Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CYBNNASDAQ:DERMNASDAQ:EPRXNASDAQ:VACC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYBNCybin$6.56+2.8%$6.73$4.81▼$13.88$140.89M0.6242,225 shs211,171 shsDERMJourney Medical$7.10+18.9%$6.41$3.20▼$8.24$164.04M0.8683,093 shs384,825 shsEPRXEupraxia Pharmaceuticals$3.80-3.6%$3.61$2.20▼$4.48$136.23MN/A14,693 shs14,184 shsVACCVaccitech$0.89-2.2%$1.57$1.64▼$5.10$34.31M-0.4244,643 shs3,638 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYBNCybin-3.19%+2.74%-17.14%-32.63%+1,629.00%DERMJourney Medical-5.54%-13.75%-3.86%+15.03%+65.37%EPRXEupraxia Pharmaceuticals+1.81%+3.96%+27.10%+21.60%+33.56%VACCVaccitech-2.18%-9.03%+29.34%-14.17%-61.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYBNCybin2.2748 of 5 stars3.60.00.00.01.90.81.3DERMJourney Medical2.4485 of 5 stars3.62.00.00.02.81.70.6EPRXEupraxia Pharmaceuticals3.0975 of 5 stars3.83.00.00.03.30.00.6VACCVaccitechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYBNCybin 3.25Buy$86.001,210.98% UpsideDERMJourney Medical 3.20Buy$9.8839.08% UpsideEPRXEupraxia Pharmaceuticals 3.50Strong Buy$10.50176.32% UpsideVACCVaccitech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VACC, DERM, EPRX, and CYBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/27/2025DERMJourney MedicalIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$10.503/27/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/13/2025CYBNCybinGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.002/21/2025EPRXEupraxia PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYBNCybinN/AN/AN/AN/A$10.83 per shareN/ADERMJourney Medical$56.13M2.92$0.25 per share28.37$1.05 per share6.76EPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$0.03 per shareN/AVACCVaccitech$13.42M2.56$0.05 per share19.30$6.52 per share0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/ADERMJourney Medical-$3.85M-$0.74N/AN/AN/A-31.74%-132.10%-26.90%N/AEPRXEupraxia Pharmaceuticals-$28.22M-$0.76N/AN/AN/AN/A-219.64%-96.00%N/AVACCVaccitech$5.34M-$1.43N/AN/AN/A-409.18%-23.41%-20.85%N/ALatest VACC, DERM, EPRX, and CYBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/6/2025Q1 2025EPRXEupraxia Pharmaceuticals-$0.19-$0.21-$0.02-$0.21N/AN/A3/26/2025Q4 2024DERMJourney Medical-$0.22$0.08+$0.30$0.08$14.21 million$14.30 million3/20/2025Q4 2024EPRXEupraxia Pharmaceuticals-$0.20-$0.21-$0.01-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYBNCybinN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AVACCVaccitechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYBNCybinN/A24.2424.24DERMJourney Medical1.811.381.03EPRXEupraxia PharmaceuticalsN/A4.174.17VACCVaccitechN/A15.2615.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYBNCybin17.94%DERMJourney Medical7.25%EPRXEupraxia PharmaceuticalsN/AVACCVaccitech26.13%Insider OwnershipCompanyInsider OwnershipCYBNCybin15.00%DERMJourney Medical13.16%EPRXEupraxia PharmaceuticalsN/AVACCVaccitech6.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYBNCybin5021.48 million17.96 millionNot OptionableDERMJourney Medical9023.10 million18.14 millionN/AEPRXEupraxia Pharmaceuticals2935.85 millionN/AN/AVACCVaccitech3338.55 million36.23 millionNot OptionableVACC, DERM, EPRX, and CYBN HeadlinesRecent News About These CompaniesVTP-500 by Barinthus Biotherapeutics for Middle East Respiratory Syndrome (MERS): Likelihood of ApprovalDecember 31, 2024 | pharmaceutical-technology.comReal-World Data on the RSV Vaccine for Older AdultsNovember 12, 2024 | msn.com10 Startups Founded Out Of Oxford UniversityNovember 5, 2024 | techround.co.ukNigeria: Ten Things to Know About New R21 Malaria Vaccine Nigeria ReceivedOctober 18, 2024 | allafrica.comTen things to know about new R21 malaria vaccine Nigeria receivedOctober 18, 2024 | premiumtimesng.comBarinthus Bio completes enrolment in hepatitis B and prostate cancer vaccine trialsOctober 2, 2024 | finance.yahoo.comBuy Rating Affirmed on Barinthus Biotherapeutics Amid Promising Clinical Trials and Therapeutic AdvancesOctober 1, 2024 | markets.businessinsider.comBarinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate CancerOctober 1, 2024 | markets.businessinsider.comStrong Buy Rating for Barinthus Biotherapeutics Amid Promising Trials in Celiac and Hepatitis B TherapiesSeptember 26, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Barinthus Biotherapeutics Amid Promising Clinical AdvancementsAugust 12, 2024 | markets.businessinsider.comBRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024August 9, 2024 | markets.businessinsider.comGiving RSV and Flu Vaccines Together Led to Adequate Immune ResponsesAugust 7, 2024 | medpagetoday.comHow real are the threats to the US dollar?July 31, 2024 | uk.finance.yahoo.comZoster Vaccine Market to Reach $9.1 Billion by 2033; Increasing Cases of Herpes Zoster Drives the Market's GrowthJuly 29, 2024 | finance.yahoo.comGoogle invests in UK vaccine pioneer VaccitechJuly 26, 2024 | pharmaphorum.comBarinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024May 22, 2024 | markets.businessinsider.comBuy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical TrialsMay 17, 2024 | markets.businessinsider.comReal reasons Nigeria still missing out on malaria vaccine rolloutMay 11, 2024 | premiumtimesng.comChutes & Ladders—BridgeBio oncology execs take the reins of new spinoutMay 3, 2024 | fiercebiotech.comNews - Leon HooftmanMay 1, 2024 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVACC, DERM, EPRX, and CYBN Company DescriptionsCybin NYSE:CYBN$6.56 +0.18 (+2.82%) As of 04:00 PM EasternCybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Journey Medical NASDAQ:DERM$7.10 +1.13 (+18.93%) As of 04:00 PM EasternJourney Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Eupraxia Pharmaceuticals NASDAQ:EPRX$3.80 -0.14 (-3.55%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Vaccitech NASDAQ:VACCVaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
